Company Overview
AIM ImmunoTech Inc. operates as an immuno-pharma company dedicated to the research and development of therapeutics designed to treat multiple types of cancers, viral diseases, and immune-deficiency disorders within the United States market. The company functions within the Healthcare sector and specifically within the Biotechnology industry, an environment characterized by high research expenditures and a focus on novel drug candidates rather than immediate profitability. In terms of scale, AIM ImmunoTech Inc. holds a market capitalization of $2.95M, generates annual revenue of $112,000, and employs 21 staff members to support its operational activities. The combination of a market cap of $2.95M and revenue of $112,000 indicates that the company is a micro-cap biotechnology entity with limited market presence, where its valuation is derived primarily from its development pipeline rather than established cash flows.
Financial Health
The company reported revenue of $112,000 over the trailing twelve months, while simultaneously posting a net income of $-15,750,000 and an EBITDA of $-14,336,000. The significant gap between the modest revenue of $112,000 and the substantial net loss of $-15,750,000 reveals a cost structure dominated by heavy research and development expenses and operating costs that far exceed current sales. Free cash flow stands at $-14,186,000, which indicates that the company is burning through its capital reserves to fund operations and development efforts without generating sufficient operational cash to sustain itself without external financing. Gross margin is calculated at 15.2%, suggesting that while product costs are managed to some extent, the low revenue base prevents significant gross profit generation. Operating margin stands at -9411.5%, highlighting extreme operational inefficiency relative to sales, while profit margin is 0.0%, reflecting the absence of net profit in the current period. Total cash on hand is $2.41M, which is slightly higher than the total debt of $2.34M, yet the debt-to-equity ratio is listed as N/A, preventing a traditional leverage assessment. Despite having more cash than debt, the company's liquidity position is constrained by a current ratio of 0.64, indicating that current liabilities exceed current assets and signaling potential short-term liquidity pressure. Return on Equity is N/A due to the lack of attributable net income, while Return on Assets is -95.4%, revealing that the company's asset base is generating significant negative returns relative to its investment.
Valuation Assessment
The P/E Ratio (TTM) is N/A because the company has no net income, whereas the Forward P/E is -0.16, a negative figure that precludes standard valuation comparisons based on earnings multiples. The price-to-book ratio is -0.32, a negative metric that indicates the company's market capitalization is theoretically below its book value, a common characteristic for pre-revenue or loss-making biotechnology firms where intangible assets are not fully captured on the balance sheet. The price-to-sales ratio is 26.38, and the EV/EBITDA is -0.13; these alternative metrics suggest that the market is valuing the company primarily on its potential future revenue and pipeline value rather than current profitability or earnings. The 52-week high is $34.92 and the 52-week low is $0.61, meaning the stock is currently trading significantly closer to the low end of its historical range given the wide volatility typical of small-cap biotech stocks. The beta value is 1.25, which implies that the stock price is expected to be 25% more volatile than the broader market, reflecting the high risk premium associated with early-stage biotechnology investments.
Growth & Income
Revenue growth (YoY) is -25.7%, and earnings growth (YoY) is N/A due to the company's lack of recent profitability. Since the company is not profitable, the concept of earnings growing faster or slower than revenue does not apply in a traditional sense, but the decline in revenue suggests a contraction in sales or business activity. The dividend yield is N/A and the payout ratio is 0.0%, indicating that the company does not distribute any dividends to shareholders. As a non-dividend payer, AIM ImmunoTech Inc. reinvests its limited earnings and cash reserves entirely into research and development efforts rather than paying out income to investors. The overall growth and income profile is defined by negative revenue growth and a total absence of dividend income, characteristic of a development-stage biotechnology company relying on capital markets for survival and expansion.